Table 3.
The baseline characteristics of survivors and non-survivors in patients with COVID-19 with diabetes
| Variable | Total (n=1365) | Survivors (n=1169) | Non-survivors (n=196) | p value |
|---|---|---|---|---|
| Number (%) | Number (%) | Number (%) | ||
| Age, median (IQR) | 59 (49–67) | 57 (48–66) | 66 (57–73) | <0.001 |
| Gender | ||||
| Male | 607 (44.50) | 488 (44.30) | 98 (50.00) | 0.141 |
| Female | 758 (55.50) | 613 (55.70) | 98 (50.00) | |
| Symptoms | ||||
| Fever | 1075 (78.80) | 874 (79.40) | 162 (82.70) | 0.293 |
| Cough | 1035 (75.80) | 861 (78.20) | 156 (79.60) | 0.663 |
| Dyspnea | 902 (66.08) | 755 (68.60) | 147 (75.00) | 0.072 |
| Muscular pain | 106 (7.76) | 93 (7.95) | 13 (6.63) | 0.393 |
| Diarrhea | 23 (1.68) | 22 (1.88) | 1 (0.51) | 0.146 |
| Nausea | 29 (2.12) | 25 (2.13) | 4 (2.04) | 0.841 |
| Sore throat | 68 (4.98) | 63 (5.38) | 5 (2.55) | 0.066 |
| Comorbidities | ||||
| Hypertension | 391 (28.64) | 324 (27.71) | 67 (34.18) | 0.181 |
| Cardiovascular disease | 249 (18.24) | 193 (16.50) | 56 (28.57) | <0.001 |
| Immunodeficiency | 20 (1.46) | 17 (1.45) | 3 (1.53) | 0.989 |
| Chronic kidney disease | 71 (5.20) | 57 (4.87) | 14 (7.14) | 0.265 |
| Chronic pulmonary disease | 53 (3.88) | 45 (3.84) | 8 (4.08) | 0.997 |
| Chronic liver disease | 13 (0.95) | 12 (1.02) | 1 (0.51) | 0.453 |
| Exposure to disease | 690 (50.54) | 599 (51.24) | 91 (46.42) | 0.039D |